Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0015672 (fatigue)
 51,768 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Abacavir sulfate (Ziagen) received accelerated approval for treatment of HIV infection from the Food and Drug Administration (FDA). It is the fifteenth approved anti-HIV drug. Abacavir, manufactured by Glaxo Wellcome, is currently the most powerful of the nucleoside analogue reverse transcriptase inhibitors (NRTIs). Side effects include nausea, vomiting, fatigue, headache, and diarrhea. A serious hypersensitivity reaction occurs in approximately 5 percent of patients taking the drug. Patients who experience this reaction can never take the drug again, because subsequent reactions can be fatal. Drug interactions may be minimal, as abacavir is not metabolized by the same enzymes that metabolize several other anti-retrovirals. Resistance is also discussed and clinical data from studies are presented.
 ...
PMID:Abacavir sulfate (Ziagen). 1136 89

Information on dosage, cost, side effects, and interactions is provided for each of the seven nucleoside analog drugs available currently: Retrovir (AZT, ZDV), Videx (ddI), Hivid (ddC), Zerit (d4T), Epivir (3TC), Combivir (AZT/3TC), and Ziagen (abacavir sulfate). Most nucleoside analogs (with the exception of ddI) do not have food restrictions, but do have potential side effects such as nausea and fatigue. An activist, a doctor, and the drug's manufacturer offer comments. Contact information is provided.
 ...
PMID:What they say about nucleoside drugs. 1136 20

Abacavir (Ziagen), a nucleoside analog used in combination therapy, can cause a hypersensitivity reaction in as many as five percent of patients. When this reaction occurs, the drug must be stopped immediately and never restarted. The hypersensitivity can cause fever, rash, gastrointestinal symptoms, fatigue, and life-threatening hypotension. The reaction generally occurs in the first six weeks of treatment. The risk of hypersensitivity has long been recognized, but it is often misdiagnosed as a respiratory ailment. Glaxo Wellcome sent out a letter in January 2000 to warn health care providers about the reaction and how to diagnose it; the full text of that letter is included. The manufacturer has also relabeled the drug with stronger warnings; the Web site address is provided for further information on the change in labeling.
 ...
PMID:Abacavir warning: certain respiratory symptoms can indicate hypersensitivity reaction. 1136 10